Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01563601
Recruitment Status : Withdrawn (Business Decision)
First Posted : March 27, 2012
Last Update Posted : August 15, 2012
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )

Tracking Information
First Submitted Date  ICMJE March 15, 2012
First Posted Date  ICMJE March 27, 2012
Last Update Posted Date August 15, 2012
Study Start Date  ICMJE August 2012
Estimated Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 23, 2012)
Overall survival (OS): Time to Death [ Time Frame: 24 months from last patient enrolled ]
After 570 death events have been observed (Interim Analysis after 171 death events)or 24 months from last patient enrolled
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01563601 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 23, 2012)
  • Progression-Free Survival (PFS) [ Time Frame: 24 months from last patient enrolled ]
    Randomization to Date of First Documented Disease Progression or Death for up to 24 months from last patient enrolled
  • Duration of Response [ Time Frame: 24 months from last patient enrolled ]
    First Response to Disease Progression or Death up to 24 months from last patient enrolled
  • Objective Response Rate (Complete Response or Partial Response) [ Time Frame: 37 months ]
  • Quality of Life [ Time Frame: 37 months ]
    This is assessed with the European Organization for Research and Treatment of Cancer(EORTC)QLQ-C30 and EORTC QLQ-LC13 questionnaires
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Official Title  ICMJE A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Brief Summary This is a randomized, multi-center, open-label study of approximately 24 months duration (including follow up survival) to evaluate the safety and efficacy of obatoclax mesylate in combination with carboplatin and etoposide versus carboplatin and etoposide alone in chemotherapy-naive patients with extensive-stage small cell lung cancer.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Extensive-stage Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Obatoclax Mesylate, Carboplatine and Etoposide

    Obatoclax Mesylate:

    30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.

    Carboplatin:

    Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles

    Etoposide:

    100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles

    Other Names:
    • Obatoclax: CEP-41601
    • Carboplatin: Paraplatin
    • Etoposide: Eposin, Neoposid, Vepesid, Etopophos
  • Drug: Carboplatin and Etoposide

    Carboplatin:

    Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.

    Etoposide:

    100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles

    Other Names:
    • Carboplatin: Paraplatin
    • Etoposide: Eposin, Neoposid, Vepesid, Etopophos
Study Arms  ICMJE
  • Experimental: Obatoclax mesylate, Carboplatin and Etoposide (CEO)
    Intervention: Drug: Obatoclax Mesylate, Carboplatine and Etoposide
  • Active Comparator: Carboplatin and Etoposide (CE)
    Intervention: Drug: Carboplatin and Etoposide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: August 14, 2012)
0
Original Estimated Enrollment  ICMJE
 (submitted: March 23, 2012)
748
Estimated Study Completion Date  ICMJE January 2018
Estimated Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • The patient has histologic or cytologic confirmation (upon local review) of small cell lung cancer (SCLC).
  • The patient has extensive-stage small cell lung cancer (ES-SCLC), as defined by National Comprehensive Cancer Network (NCCN) guidelines.
  • The patient has measurable disease as assessed by Response Evaluation Criteria Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
  • The patient has not received any prior chemotherapy, biological agent, or investigational drug for SCLC.
  • The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • The patient is 18 years of age or older at the time informed consent is obtained.
  • The patient must be accessible for study treatment and follow-up. Patients enrolled in this study must be treated at participating study centers for all 3 days of study drug administration in either treatment group.
  • The patient has normal organ function.
  • Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to study enrollment. Women of childbearing potential and men with partners of childbearing potential must use a highly effective method of contraception throughout the entire study and up to 8 weeks after the last dose of any study drug (including obatoclax maintenance). Effective contraception or birth control is defined as those with a low failure rate (less than 1% per year) when used consistently and correctly.
  • Women must not be breastfeeding.
  • Written informed consent is obtained.
  • Patients with asymptomatic brain metastases may be enrolled and if clinically indicated, may be treated with steroids to be tapered as tolerated by the patient. Patients with symptomatic brain metastases will be eligible for the study after they have received therapeutic whole brain irradiation (WBI), which must be completed at least 7 days before the day of first treatment with study drugs. Since these patients will also be treated with steroids it is recommended that steroids be tapered as clinically indicated and tolerated by the patient. The use of chronic, low-dose steroids is not contraindicated for these patients (or any other patients). Stereotactic radiation will be allowed for 1 to 3 brain metastatic lesions that meet appropriate criteria for that procedure; however, this must be discussed with the study monitor prior to consideration for enrollment into this study.
  • The patient must be willing and able to comply with study restrictions and to remain at the study center for the required duration during the study period and willing to return to the study center for the follow-up evaluation as specified in this protocol.

Exclusion Criteria:

  • The patient has had any prior systemic therapy for ES-SCLC other than radiation therapy or surgery.
  • The patient has a history of prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell or squamous cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy and is deemed by his or her treating physician to be at low risk for recurrence for 5 years.
  • The patient has a history of hypersensitivity or allergic reactions attributed to components of the obatoclax mesylate formulation (ie, polysorbate 20 and polyethylene glycol [PEG] 300) or to carboplatin or etoposide.
  • The patient currently has leptomeningeal disease or paraneoplastic syndromes.
  • The patient has uncontrolled intercurrent illness including, but not limited to, symptomatic neurologic illness; active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment; symptomatic congestive heart failure; unstable angina pectoris; clinically significant cardiac arrhythmia; significant pulmonary disease or hypoxia; or psychiatric illness that would limit compliance with study requirements.
  • The patient is a pregnant or lactating woman. (Any women becoming pregnant during the study will be withdrawn from the study but will be monitored for safety.)
  • The patient has a positive test result for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus (HCV Ab) or a known positive history of antibodies to human immunodeficiency virus (HIV) and is receiving combination antiretroviral therapy.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01563601
Other Study ID Numbers  ICMJE C41601/3099
2011-005591-41 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Teva Pharmaceutical Industries ( Cephalon )
Study Sponsor  ICMJE Cephalon
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Teva Pharmaceutical Industries
Verification Date August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP